ResMed Inc. (RMD) 의 후행 P/E는 22.4, 선행 P/E 20.9. 후행 이익수익률은 4.46%, 선행 이익수익률 4.79%. PEG 0.60 (Peter Lynch 저평가 ≤1.0). 그레이엄 넘버는 $99.25.
이 페이지에서 입증된 기준:
SharesGrow 종합 점수: 78/100 5/7 개 기준 통과.
| Year | P/E (TTM) | PEG 비율 | P/B 비율 | P/S 비율 | 배당 수익률 |
|---|---|---|---|---|---|
| 2016 | 25.2 | 0.00 | 5.23 | 4.82 | 1.90% |
| 2017 | 32.2 | -8.97 | 5.62 | 5.33 | 1.69% |
| 2018 | 46.9 | -5.40 | 7.18 | 6.32 | 1.35% |
| 2019 | 43.8 | 1.56 | 8.55 | 6.79 | 1.20% |
| 2020 | 44.6 | 0.85 | 11.10 | 9.37 | 0.81% |
| 2021 | 75.5 | -3.13 | 12.41 | 11.21 | 0.63% |
| 2022 | 39.3 | 0.62 | 9.11 | 8.56 | 0.80% |
| 2023 | 35.7 | 2.45 | 7.76 | 7.59 | 0.81% |
| 2024 | 26.9 | 2.01 | 5.65 | 5.87 | 1.03% |
| 2025 | 27.0 | 0.72 | 6.34 | 7.36 | 0.82% |
| Year | EPS (희석) | 매출 | 순이익 | 순이익률 |
|---|---|---|---|---|
| 2016 | $2.49 | $1.84B | $352.41M | 19.2% |
| 2017 | $2.40 | $2.07B | $342.28M | 16.6% |
| 2018 | $2.19 | $2.34B | $315.59M | 13.5% |
| 2019 | $2.80 | $2.61B | $404.59M | 15.5% |
| 2020 | $4.27 | $2.96B | $621.67M | 21% |
| 2021 | $3.24 | $3.2B | $474.51M | 14.8% |
| 2022 | $5.30 | $3.58B | $779.44M | 21.8% |
| 2023 | $6.09 | $4.22B | $897.56M | 21.3% |
| 2024 | $6.92 | $4.69B | $1.02B | 21.8% |
| 2025 | $9.51 | $5.15B | $1.4B | 27.2% |
| Year | EPS (평균) | EPS 범위 | 매출 (평균) | 매출 범위 | 애널리스트 수 |
|---|---|---|---|---|---|
| 2026 | $11.05 | $10.69 – $11.28 | $5.64B | $5.57B – $5.68B | 13 |
| 2027 | $12.27 | $11.47 – $12.61 | $6.07B | $5.97B – $6.12B | 13 |
| 2028 | $13.43 | $12.12 – $14.29 | $6.48B | $6.48B – $6.49B | 9 |
| 2029 | $14.38 | $14.13 – $14.59 | $6.97B | $6.88B – $7.05B | 3 |
| 2030 | $16.20 | $15.91 – $16.44 | $7.79B | $7.68B – $7.88B | 4 |
